Julia Wang Named Chief Financial Officer Beginning December 2, 2024BURLINGTON, N.C., Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer (CFO) Glenn Eisenberg will retire from the company and Julia Wang will join on December 2, 2024, as Executive Vice President and Chief Financial Officer. Mr. Eisenberg will remain at Labcorp as Special Advisor to the CEO through April ...

Labcorp Holdings Inc. (LH) , or Labcorp, is positioning itself for sustained growth with a series of strategic acquisitions and partnerships. With a growing emphasis on cell and gene therapy, the company aims to become a preferred development lab by leveraging its drug development expertise, scientific prowess and pharma relationships. The LaunchPad initiative also nears its targeted goal, which is highly promising. However, adverse macroeconomic impacts and currency fluctuations may dent the company’s grow ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number 1-11353 LABCORP HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 99-2588107 (State or other juri ...

文章核心观点 - 公司在第三季度的调整后每股收益为3.50美元,同比增长3.6%,超出市场预期[1] - 公司第三季度收入为32.8亿美元,同比增长7.2%,也超出市场预期[2] - 诊断实验室业务收入同比增长8.9%,生物医药实验室服务业务收入同比增长2.6%[3] - 公司毛利率和经营利润率均有所下降,主要受到成本和费用上升的影响[4] - 公司更新了2024年全年指引,各项指标中值均有所提升[5][6] 公司表现 财务数据 - 第三季度调整后每股收益为3.50美元,同比增长3.6%,超出市场预期[1] - 第三季度GAAP每股收益为2.00美元,同比增长5.2%[1] - 第三季度收入为32.8亿美元,同比增长7.2%,超出市场预期[2] - 其中诊断实验室业务收入同比增长8.9%,生物医药实验室服务业务收入同比增长2.6%[3] - 毛利率下降29个基点至27.6%,主要由于收入成本上升7.8%[4] - 经营利润率下降42个基点至10.2%,主要由于销售费用上升8.2%[4] 现金流和财务状况 - 第三季度末现金及现金等价物为15.2亿美元,较上季度末增加12.55亿美元[5] - 长期债务较上季度末增加75.4%至53.5亿美元[5] - 第三季度经营活动产生的现金流入为8.086亿美元,同比增加29.9%[5] 战略发展 - 公司通过收购等方式继续扩大诊断和生物医药实验室服务业务[8] - 在科技创新方面推出了新的客户服务体验和消费者自主检测服务[8] - 还在妇女健康解决方案领域进行了拓展[8] 行业展望 - 公司更新了2024年全年指引,各项指标中值均有所提升[5][6] - 2024年全年收入预计增长6.6%-7.3%,诊断实验室业务收入预计增长7.2%-7.8%,生物医药实验室服务业务收入预计增长4.7%-5.6%[5] - 2024年全年调整后每股收益预计为14.30-14.70美元[6] - 2024年全年自由现金流预计为8.5-9.8亿美元[6]

For the quarter ended September 2024, Labcorp (LH) reported revenue of $3.28 billion, up 7.4% over the same period last year. EPS came in at $3.50, compared to $3.38 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $3.26 billion, representing a surprise of +0.64%. The company delivered an EPS surprise of +0.57%, with the consensus EPS estimate being $3.48.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expec ...

Labcorp (LH) came out with quarterly earnings of $3.50 per share, beating the Zacks Consensus Estimate of $3.48 per share. This compares to earnings of $3.38 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 0.57%. A quarter ago, it was expected that this medical laboratory operator would post earnings of $3.78 per share when it actually produced earnings of $3.94, delivering a surprise of 4.23%.Over the last four quarters, the ...

FOR IMMEDIATE RELEASE Contact: Christin O'Donnell (investors) Investor@Labcorp.com Kimbrel Arculeo (media) Media@Labcorp.com Labcorp Announces 2024 Third Quarter Results Updates Full-Year Guidance • Results from Continuing Operations for third quarter 2024 versus last year: ◦ Revenue: $3.28 billion versus $3.06 billion ◦ Diluted EPS: $2.00 versus $2.11 ◦ Adjusted EPS: $3.50 versus $3.38 ◦ Free Cash Flow: $162 million versus $171 million • Updated Full-Year 2024 Guidance: ◦ Revenue range of 6.6% to 7.3%; mid ...

Updates Full-Year GuidanceResults from Continuing Operations for third quarter 2024 versus last year:Revenue: $3.28 billion versus $3.06 billionDiluted EPS: $2.00 versus $2.11Adjusted EPS: $3.50 versus $3.38Free Cash Flow: $162 million versus $171 millionUpdated Full-Year 2024 Guidance:Revenue range of 6.6% to 7.3%; midpoint unchangedAdjusted EPS range of $14.30 to $14.70; midpoint down $0.10, due to the negative impact from weather of approximately $0.15Free Cash Flow of $850 million to $980 millionAnnounc ...

Wall Street analysts expect Labcorp (LH) to post quarterly earnings of $3.49 per share in its upcoming report, which indicates a year-over-year increase of 3.3%. Revenues are expected to be $3.26 billion, up 6.7% from the year-ago quarter.The consensus EPS estimate for the quarter has been revised 0.8% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Ahead of a company's earnings di ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Labcorp (LH) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on October 24. On ...